Protagonist therapeutics announces poster presentation on final revive phase 2 study data with rusfertide at the 66th annual ash meeting

Newark, ca / accesswire / november 5, 2024 / protagonist therapeutics, inc. ("protagonist" or the "company") announced that final data from the phase 2 revive study with rusfertide in polycythemia vera will be the focus of a poster presentation at the 66th annual american society of hematology (ash) annual meeting being held in san diego from december 7-10, 2024. ash presentation details: presenting author: aaron gerds, md (cleveland clinic) publication number: 4559 title: final results from the phase 2 revive study investigating the hepcidin mimetic rusfertide in patients with polycythemia vera (pv) session name: 634.
ASH Ratings Summary
ASH Quant Ranking